

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

PATENT ASSIGNEE(S) :

STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES
CytoGen Corporation (U.S. corporation)

PATENT INFORMATION:

NUMBER KIND DATE

US 2007010441 A1 20070111

APPLICATION INFO.:

US 2006-356452 A1 20060217 (11)

RELATED APPLN. INFO.:

Division of Ser. No. US 1998-79678, filed on 15 May
1998, GRANTED, Pat. No. US 7053177.

PRIORITY INFORMATION:

NUMBER DATE

US 1997-46595P 19970515 (60)

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE
NW, WASHINGTON, DC, 20004, US

NUMBER OF CLAIMS:

31

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

48 Drawing Page(s)

LINE COUNT:

8505

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 5 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006297361 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES

O'Mahony, Daniel J., Dublin, IRELAND

Lambkin, Imelda J., Dublin, IRELAND

Patterson, Catherine A., Dublin, IRELAND

Singleton, Judith, Rocky Hill, NJ, UNITED STATES

Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES

Carter, John M., Trenton, NJ, UNITED STATES

Cagney, Gerard M., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): CytoGen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)

Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

NUMBER KIND DATE

PATENT INFORMATION:

NUMBER KIND DATE

US 7135457 B1 20061114

APPLICATION INFO.:

US 1998-79819 19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 48 Drawing Page(s)	
LINE COUNT:	8630	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 3 OF 5 USPATFULL on STN
 TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
 AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2006:133579 USPATFULL
TITLE:	Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
INVENTOR(S):	Alvarez, Vernon L., Morrisville, PA, UNITED STATES O'Mahony, Daniel J., Dublin, IRELAND Lambkin, Imelda J., Dublin, IRELAND Patterson, Catherine A., Dublin, IRELAND Singleton, Judith, Rocky Hill, NJ, UNITED STATES Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES Carter, John M., Trenton, NJ, UNITED STATES Cagney, Gerard M., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S):	Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)

PATENT INFORMATION:	NUMBER	KIND	DATE
APPLICATION INFO.:	US 7053177	B1	20060530
	US 1998-79678		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Campell, Bruce R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	4580	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L3 ANSWER 4 OF 5 USPATFULL on STN
TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:59889 USPATFULL
TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, United States
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, United States
Belinka, Jr., Benjamin A., Kendall Park, NJ, United States
Carter, John M., Trenton, NJ, United States
Cagney, Gerard M., Seattle, WA, United States
PATENT ASSIGNEE(S): CytoGen Corporation, Princeton, NJ, United States (U.S. corporation)
Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6703362	B1	20040309
APPLICATION INFO.:	US 1998-79723		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	13	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	38 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	9164	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 5 USPATFULL on STN
TI Antibodies to peptides that target GIT receptors and related methods
AB The invention provides an antibody or antibody fragment specific to a domain of a GIT targeting agent, such as a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody, a Fab fragment or a Fab expression library. In particular, the invention provides an antibody or antibody fragment, wherein the GIT targeting agent is selected from the group consisting of ZElan033 (PAX2 15 mer), ZElan088 (HAX42-2 20 mer) or ZElan053 (P31 D-form 16 mer). Numerous methods using these GIT targeting agent specific antibodies are

disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:53408 USPATFULL
TITLE: Antibodies to peptides that target GIT receptors and related methods
INVENTOR(S): O'Mahony, Daniel Joseph, Blackrock, IRELAND
Seveso, Michela, Padua, ITALY
PATENT ASSIGNEE(S): Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6699973	B1	20040302
APPLICATION INFO.:	US 1999-443780		19991119 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-109036P	19981119 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Scheiner, Laurie	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1417	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 11:48:44 ON 10 FEB 2007)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE' ENTERED AT 11:49:20 ON 10 FEB 2007

L1 567 S (HPEPT1)
L2 73 S L1 AND FUSION PROTEIN
L3 5 S L1 AND (HIS-TAG)

=> s l2 and (retro-inverted peptide)
L4 0 L2 AND (RETRO-INVERTED PEPTIDE)

=> s l1 and receptor
L5 293 L1 AND RECEPTOR

=> s l5 and (retro-inverted peptide)
L6 8 L5 AND (RETRO-INVERTED PEPTIDE)

=> d l6 ti abs ibib tot

L6 ANSWER 1 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
AN AAB03872 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also

disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length HAX42 amino acid sequence.

ACCESSION NUMBER: AAB03872 peptide DGENE

TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602

36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan021 (full length HAX42).

L6 ANSWER 2 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03871 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is the full length PAX2 amino acid sequence.

ACCESSION NUMBER: AAB03871 peptide DGENE

TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia,

anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan018 (full length PAX2).

L6 ANSWER 3 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03870 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro-
inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active
ingredients through human or animal gastrointestinal tissue, from the
lumen to the portal, hepatic, or systemic circulation. The compositions
containing these agents can be used to treat or prevent mammalian,
especially human, diseases or disorders, especially hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and
angina pectoris. The compositions can be administered in vivo to image
selected sites or tissues, such as the gastrointestinal tract, by using
an imaging agent as the active agent. The present sequence represents a
peptide from which a retro-inversion peptide of the invention is created.
The peptide is a fragment of HAX42.

ACCESSION NUMBER: AAB03870 peptide DGENE
TITLE: Retro-inverted peptide used to
deliver active agents across the gastrointestinal tract to
treat hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan091 (HAX42
fragment).

L6 ANSWER 4 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03869 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind

to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of P31.

ACCESSION NUMBER: AAB03869 peptide DGENE

TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602

36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan031 (P31 fragment).

L6 ANSWER 5 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN

TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

AN AAB03868 peptide DGENE

AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using

an imaging agent as the active agent. The present sequence represents a peptide from which a retro-inversion peptide of the invention is created. The peptide is a fragment of PAX2.

ACCESSION NUMBER: AAB03868 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan129 (PAX2 fragment).

L6 ANSWER 6 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
AN AAB03867 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind to the gastro-intestinal tract receptor HPT1, hPEPT1, D2H or hSI. Also included in the invention are a retro-inverted peptide which enhances the delivery of an active agent across the gastrointestinal tract (GIT) into the systemic, portal or hepatic circulation. A composition comprising a retro-inverted peptide bound to a material comprising an active agent used to treat a mammalian disease or disorder is also disclosed in the invention. The retro-inversion peptides target gastrointestinal tract transport receptors to promote in vivo uptake of active agents and/or enhance active agent delivery across the tract into the systemic circulation. The gastrointestinal agents (containing retro-inverted peptides) are used to facilitate the transport of active ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a HAX42 14 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03867 peptide DGENE
TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan146 (HAX42 fragment).

L6 ANSWER 7 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03866 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro-
inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active
ingredients through human or animal gastrointestinal tissue, from the
lumen to the portal, hepatic, or systemic circulation. The compositions
containing these agents can be used to treat or prevent mammalian,
especially human, diseases or disorders, especially hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and
angina pectoris. The compositions can be administered in vivo to image
selected sites or tissues, such as the gastrointestinal tract, by using
an imaging agent as the active agent. The present sequence represents a
retro-inversion used in the invention. The sequence is a P31 16 mer
fragment D form retro-inversion peptide.
ACCESSION NUMBER: AAB03866 peptide DGENE
TITLE: Retro-inverted peptide used to
deliver active agents across the gastrointestinal tract to
treat hypertension, diabetes, osteoporosis, haemophilia,
anaemia, cancer, migraines and angina pectoris -
INVENTOR: O'Mahony D J
PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.
PATENT INFO: WO 2000031123 A2 20000602 36
APPLICATION INFO: WO 1999-IE117 19991119
PRIORITY INFO: US 1998-109038 19981119
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 2000-400037 [34]
DESCRIPTION: GIT receptor targeting peptide ZElan145 (P31
fragment).

L6 ANSWER 8 OF 8 DGENE COPYRIGHT 2007 The Thomson Corp on STN
TI Retro-inverted peptide used to deliver
active agents across the gastrointestinal tract to treat hypertension,
diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and
angina pectoris -
AN AAB03865 peptide DGENE
AB This invention relates to retro-inverted peptides which specifically bind
to the gastro-intestinal tract receptor HPT1, hPEPT1,
D2H or hSI. Also included in the invention are a retro-
inverted peptide which enhances the delivery of an
active agent across the gastrointestinal tract (GIT) into the systemic,
portal or hepatic circulation. A composition comprising a retro-
inverted peptide bound to a material comprising an
active agent used to treat a mammalian disease or disorder is also
disclosed in the invention. The retro-inversion peptides target
gastrointestinal tract transport receptors to promote in vivo uptake of
active agents and/or enhance active agent delivery across the tract into
the systemic circulation. The gastrointestinal agents (containing
retro-inverted peptides) are used to facilitate the transport of active

ingredients through human or animal gastrointestinal tissue, from the lumen to the portal, hepatic, or systemic circulation. The compositions containing these agents can be used to treat or prevent mammalian, especially human, diseases or disorders, especially hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraine, and angina pectoris. The compositions can be administered in vivo to image selected sites or tissues, such as the gastrointestinal tract, by using an imaging agent as the active agent. The present sequence represents a retro-inversion used in the invention. The sequence is a PAX2 15 mer fragment D form retro-inversion peptide.

ACCESSION NUMBER: AAB03865 peptide DGENE

TITLE: Retro-inverted peptide used to deliver active agents across the gastrointestinal tract to treat hypertension, diabetes, osteoporosis, haemophilia, anaemia, cancer, migraines and angina pectoris -

INVENTOR: O'Mahony D J

PATENT ASSIGNEE: (ELAN-N) ELAN CORP PLC.

PATENT INFO: WO 2000031123 A2 20000602 36

APPLICATION INFO: WO 1999-IE117 19991119

PRIORITY INFO: US 1998-109038 19981119

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 2000-400037 [34]

DESCRIPTION: GIT receptor targeting peptide ZElan144 (PAX2 fragment).

=> d his

(FILE 'HOME' ENTERED AT 11:48:44 ON 10 FEB 2007)

FILE 'MEDLINE, BIOSIS, USPATFULL, DGENE, EMBASE' ENTERED AT 11:49:20 ON 10 FEB 2007

L1 567 S (HPEPT1)
L2 73 S L1 AND FUSION PROTEIN
L3 5 S L1 AND (HIS-TAG)
L4 0 S L2 AND (RETRO-INVERTED PEPTIDE)
L5 293 S L1 AND RECEPTOR
L6 8 S L5 AND (RETRO-INVERTED PEPTIDE)

=> s l1 and treatment

L7 306 L1 AND TREATMENT

=> s l7 and l2

L8 70 L7 AND L2

=> s l8 and (retro-inverted peptide)

L9 0 L8 AND (RETRO-INVERTED PEPTIDE)

=> s ZElan

L10 62 ZELAN

=> s l10 and l8

L11 9 L10 AND L8

=> d l11 ti abs ibib tot

L11 ANSWER 1 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and

derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2007:12027 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, UNITED STATES

O'Mahony, Daniel J., Dublin, IRELAND

Lambkin, Imelda J., Dublin, IRELAND

Patterson, Catherine A., Dublin, IRELAND

Singleton, Judith, Rocky Hill, NJ, UNITED STATES

Belinka, Benjamin A. JR., Kendall Park, NJ, UNITED STATES

Carter, John M., Trenton, NJ, UNITED STATES

Cagney, Gerard M., Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Cyrogen Corporation (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2007010441 A1 20070111

APPLICATION INFO.: US 2006-356452 A1 20060217 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-79678, filed on 15 May 1998, GRANTED, Pat. No. US 7053177

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-46595P 19970515 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US

NUMBER OF CLAIMS: 31

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 48 Drawing Page(s)

LINE COUNT: 8505

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 2 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:297361 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S) : Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S) : Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)
Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7135457	B1	20061114
APPLICATION INFO.:	US 1998-79819		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Tate, Christopher R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 48 Drawing Page(s)	
LINE COUNT:	8630	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L11 ANSWER 3 OF 9 USPATFULL on STN
TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastrointestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 2006:133579 USPATFULL
TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
INVENTOR(S) : Alvarez, Vernon L., Morrisville, PA, UNITED STATES
O'Mahony, Daniel J., Dublin, IRELAND
Lambkin, Imelda J., Dublin, IRELAND
Patterson, Catherine A., Dublin, IRELAND
Singleton, Judith, Rocky Hill, NJ, UNITED STATES
Belinka, Jr., Benjamin A., Kendall Park, NJ, UNITED STATES
Carter, John M., Trenton, NJ, UNITED STATES
Cagney, Gerard M., Seattle, WA, UNITED STATES
PATENT ASSIGNEE(S) : Cytogen Corporation, Princeton, NJ, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7053177	B1	20060530
APPLICATION INFO.:	US 1998-79678		19980515 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-46595P	19970515 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Campell, Bruce R.	
ASSISTANT EXAMINER:	Teller, Roy	
LEGAL REPRESENTATIVE:	Morgan, Lewis & Bockius	
NUMBER OF CLAIMS:	10	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	48 Drawing Figure(s); 38 Drawing Page(s)	
LINE COUNT:	4580	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 4 OF 9 USPATFULL on STN
 TI Conjugates of membrane translocating agents and pharmaceutically active agents
 AB Membrane translation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:118304 USPATFULL
 TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents
 INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND
 Lambkin, Imelda, Sutton, IRELAND
 Pinilla, Clemencia, Cardiff, CA, UNITED STATES
 Houghten, Richard, Solana Beach, CA, UNITED STATES
 PATENT ASSIGNEE(S): Sarlan Ltd., Hamilton, BERMUDA (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006100149	A1	20060511
APPLICATION INFO.:	US 2005-303372	A1	20051216 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-955656, filed on 30 Sep 2004, ABANDONED Continuation of Ser. No. US 2002-126845, filed on 19 Apr 2002, ABANDONED Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, GRANTED, Pat. No. US 6780846		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
	US 2001-287786P	20010430 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950, US	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2599	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 5 OF 9 USPATFULL on STN
 TI Conjugates of membrane translocating agents and pharmaceutically active agents

AB Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2005:118487 USPATFULL

TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents

INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND

Lambkin, Imelda, Sutton, IRELAND

Pinilla, Clemencia, Cardiff, CA, UNITED STATES

Houghten, Richard, Solana Beach, CA, UNITED STATES

PATENT ASSIGNEE(S): Sarlan Ltd., Hamilton, BERMUDA (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 2005101762	A1	20050512
---------------	----	----------

US 2004-955656	A1	20040930 (10)
----------------	----	---------------

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-126845, filed on 19 Apr 2002, ABANDONED Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, GRANTED, Pat. No. US 6780846

NUMBER	DATE
--------	------

US 1999-156246P	19990927 (60)
-----------------	---------------

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950, US

NUMBER OF CLAIMS: 37

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)

LINE COUNT: 3597

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 6 OF 9 USPATFULL on STN

TI Membrane translocating peptide drug delivery system

AB The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:211526 USPATFULL

TITLE: Membrane translocating peptide drug delivery system

INVENTOR(S): O'Mahony, Daniel J., Dublin, IRELAND

Lambkin, Imelda J., Dublin, IRELAND

PATENT ASSIGNEE(S): Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

US 6780846	B1	20040824
------------	----	----------

US 2000-671089		20000927 (9)
----------------	--	--------------

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1999-156246P 19990927 (60)
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
ASSISTANT EXAMINER: Snedden, Sheridan K
LEGAL REPRESENTATIVE: Synnestvedt & Lechner LLP
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 7 OF 9 USPATFULL on STN

TI Membrane translocating peptide drug delivery system
AB The present invention relates to a novel membrane translocating full-length peptide sequence, fragment, motif, derivative, analog or peptidomimetic thereof (MTLPs), to nucleotide sequences coding therefor, and to compositions comprising a MTLP-active agent complex and a MTLP-active particle complex. The MTLP or the nucleotide sequence coding therefor enhance movement of the active agent or of the active particle across a lipid membrane. More particularly, the present invention relates to a MTLP-active agent complex and a MTLP-active particle complex, wherein the MTLP enhances uptake of the active agent into a cell, into or out of an intracellular compartment and across a cell layer. Methods of making and methods of using MTLPs also are included.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:178962 USPATFULL
TITLE: Membrane translocating peptide drug delivery system
INVENTOR(S): O'Mahony, Daniel J., Blackrock, IRELAND
Lambkin, Imelda J., Sutton, IRELAND

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004138132	A1	20040715
APPLICATION INFO.:	US 2004-764235	A1	20040123 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-671089, filed on 27 Sep 2000, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SYNNESTVEDT & LECHNER, LLP, 2600 ARAMARK TOWER, 1101 MARKET STREET, PHILADELPHIA, PA, 191072950	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	1591	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 8 OF 9 USPATFULL on STN

TI Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods
AB This invention relates to proteins (e.g., peptides) that are capable of facilitating transport of an active agent through a human or animal gastro-intestinal tissue, and derivatives (e.g., fragments) and analogs thereof, and nucleotide sequences coding for said proteins and derivatives. The proteins of the invention have use in facilitating transport of active agents from the luminal side of the GIT into the systemic blood system, and/or in targeting active agents to the GIT. Thus, for example, by binding (covalently or noncovalently) a protein of

the invention to an orally administered drug, the drug can be targeted to specific receptor sites or transport pathways which are known to operate in the human gastrointestinal tract, thus facilitating its absorption into the systemic system.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:59889 USPATFULL

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

INVENTOR(S): Alvarez, Vernon L., Morrisville, PA, United States

O'Mahony, Daniel J., Dublin, IRELAND

Lambkin, Imelda J., Dublin, IRELAND

Patterson, Catherine A., Dublin, IRELAND

Singleton, Judith, Rocky Hill, NJ, United States

Belinka, Jr., Benjamin A., Kendall Park, NJ, United States

Carter, John M., Trenton, NJ, United States

Cagney, Gerard M., Seattle, WA, United States

PATENT ASSIGNEE(S): Cyrogen Corporation, Princeton, NJ, United States (U.S. corporation)

Elan Corporation, PLC, Dublin, IRELAND (non-U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6703362 B1 20040309

APPLICATION INFO.: US 1998-79723 19980515 (9)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1997-46595P 19970515 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Tate, Christopher R.

ASSISTANT EXAMINER: Teller, Roy

LEGAL REPRESENTATIVE: Pennie & Edmonds LLP

NUMBER OF CLAIMS: 13

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 38 Drawing Figure(s); 38 Drawing Page(s)

LINE COUNT: 9164

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L11 ANSWER 9 OF 9 USPATFULL on STN

TI Conjugates of membrane translocating agents and pharmaceutically active agents

AB Membrane translocation peptides, compositions comprising them, chimeric molecules comprising them, and methods of using them to achieve transmembrane transport of various agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2003:258314 USPATFULL

TITLE: Conjugates of membrane translocating agents and pharmaceutically active agents

INVENTOR(S): O'Mahony, Daniel, Blackrock, IRELAND

Lambkin, Imelda, Sutton, IRELAND

Pinilla, Clemencia, Cardiff, CA, UNITED STATES

Houghten, Richard, Solana Beach, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003181367 A1 20030925

APPLICATION INFO.: US 2002-126845 A1 20020419 (10)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-671089, filed on 27 Sep 2000, PENDING

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-156246P	19990927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	CAESAR, RIVISE, BERNSTEIN, COHEN & POKOTILOW, LTD., ATTN: ELAN, 12TH FLOOR, SEVEN PENN CENTER, 1635 MARKET STREET, PHILADELPHIA, PA, 19103-2212	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Page(s)	
LINE COUNT:	2144	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

Refine Search

Search Results -

Terms	Documents
7053177.pn.	1

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

Search History

DATE: Saturday, February 10, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
side by side			result set

DB=USPT; PLUR=YES; OP=OR

<u>L2</u>	7053177.pn.	1	<u>L2</u>
<u>L1</u>	7135457.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

Hit List

First Hit	<input type="button" value="Clear"/>	<input type="button" value="Generate Collection"/>	<input type="button" value="Print"/>	<input type="button" value="Fwd Refs"/>	<input type="button" value="Bkwd Refs"/>
<input type="button" value="Generate OACS"/>					

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 7053177 B1

L2: Entry 1 of 1

File: USPT

May 30, 2006

US-PAT-NO: 7053177

DOCUMENT-IDENTIFIER: US 7053177 B1

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

DATE-ISSUED: May 30, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alvarez; Vernon L.	Morrisville	PA		US
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE
Patterson; Catherine A.	Dublin			IE
Singleton; Judith	Rocky Hill	NJ		US
Belinka, Jr.; Benjamin A.	Kendall Park	NJ		US
Carter; John M.	Trenton	NJ		US
Cagney; Gerard M.	Seattle	WA		US

US-CL-CURRENT: 530/324; 424/185.1

<input type="button" value="Full"/>	<input type="button" value="Title"/>	<input type="button" value="Citation"/>	<input type="button" value="Front"/>	<input type="button" value="Review"/>	<input type="button" value="Classification"/>	<input type="button" value="Date"/>	<input type="button" value="Reference"/>	<input type="button" value="Sequences"/>	<input type="button" value="Attachments"/>	<input type="button" value="Claims"/>	<input type="button" value="KWMC"/>	<input type="button" value="Drawn D..."/>
-------------------------------------	--------------------------------------	---	--------------------------------------	---------------------------------------	---	-------------------------------------	--	--	--	---------------------------------------	-------------------------------------	---

<input type="button" value="Clear"/>	<input type="button" value="Generate Collection"/>	<input type="button" value="Print"/>	<input type="button" value="Fwd Refs"/>	<input type="button" value="Bkwd Refs"/>	<input type="button" value="Generate OACS"/>
--------------------------------------	--	--------------------------------------	---	--	--

Terms	Documents
7053177.pn.	1

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)

Hit List

First Hit	Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs
Generate OACS					

Search Results - Record(s) 1 through 1 of 1 returned.

1. Document ID: US 7135457 B1

L1: Entry 1 of 1

File: USPT

Nov 14, 2006

US-PAT-NO: 7135457

DOCUMENT-IDENTIFIER: US 7135457 B1

TITLE: Random peptides that bind to gastro-intestinal tract (GIT) transport receptors and related methods

DATE-ISSUED: November 14, 2006

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alvarez; Vernon L.	Morrisville	PA		US
O'Mahony; Daniel J.	Dublin			IE
Lambkin; Imelda J.	Dublin			IE
Patterson; Catherine A.	Dublin			IE
Singleton; Judith	Rocky Hill	NJ		US
Belinka, Jr.; Benjamin A.	Kendall Park	NJ		US
Carter; John M.	Trenton	NJ		US
Cagney; Gerard M.	Seattle	WA		US

US-CL-CURRENT: 514/12; 424/185.1, 514/15, 514/21, 530/324, 530/327, 530/350

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMPC	Drawn D.
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	------	----------

Clear	Generate Collection	Print	Fwd Refs	Bkwd Refs	Generate OACS
-------	---------------------	-------	----------	-----------	---------------

Terms	Documents
7135457.pn.	1

Display Format: CIT

[Previous Page](#) [Next Page](#) [Go to Doc#](#)